‘Pfizer Inc. - Product Pipeline Review - 2016’, provides an overview of the Pfizer Inc.’s pharmaceutical research and development focus.

PUNE, INDIA, April 14, 2016 /EINPresswire.com/ -- The report “Pfizer Inc. - Product Pipeline Review – 2016“ provides comprehensive information on the therapeutics under development by Pfizer Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Access a Report Copy @ https://www.wiseguyreports.com/reports/pfizer-inc-product-pipeline-review-2016 .

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Pfizer Inc.
- The report provides overview of Pfizer Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Pfizer Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Pfizer Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Purchase a 1-User License Copy @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=393577 .

Reasons to buy

- Evaluate Pfizer Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pfizer Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pfizer Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Major Point in Table of Content

Pfizer Inc. - Drug Profiles 42
(naltrexone hydrochloride + oxycodone hydrochloride) ER 42
crizotinib 44
palbociclib 48
tofacitinib 52
epoetin zeta 56
gemtuzumab ozogamicin 58
tafamidis meglumine 59
(ertugliflozin + metformin hydrochloride) 61
(ertugliflozin + sitagliptin phosphate) 62
adalimumab biosimilar 63
axitinib 64
bevacizumab biosimilar 68
bococizumab 69
bosutinib 70
celecoxib 73
dacomitinib 75
ertugliflozin 78
gosogliptin 80
infliximab biosimilar 81
inotuzumab ozogamicin 82
meningococcal [serotype B] vaccine 84
pregabalin 86
pregabalin CR 88
rituximab biosimilar 89
rivipansel sodium 90
sildenafil citrate 93
sunitinib malate 95
tanezumab 99
trastuzumab biosimilar 102
ziprasidone mesylate 103
ascrinvacumab 104
Dekavil 105
domagrozumab 106
fosdagrocorat 107
gedatolisib 108
glasdegib 110
lorlatinib 112
Nimenrix 114
nirogacestat 117
PF-00489791 119
PF-00547659 120
PF-02545920 122
PF-04236921 124
PF-04457845 125
PF-05089771 126
PF-06290510 128
PF-06291874 130
PF-06425090 131
PF-06838435 132
ponezumab 133
temsirolimus 135
agatolimod sodium 137
pegfilgrastim 140
PF-06747775 141
filgrastim 142
HIV vaccine 143
PF-04136309 144
PF-04447943 146
PF-04518600 147
PF-04958242 148
PF-05082566 150
PF-05206388 152
PF-05230907 153
PF-05251749 154
PF-05402536 155
PF-06266047 156
PF-06273340 157
PF-06282999 158
PF-06293620 159
PF-06342674 160
PF-06412562 161
PF-06413367 162
PF-06427878 163
PF-06444752 164
PF-06444753 166
PF-06480605 167
PF-06647020 168
PF-06647263 169
PF-06648671 170
PF-06649751 171
PF-06650808 172
PF-06650833 173
PF-06651600 174
PF-06664178 175
PF-06669571 176
PF-06678552 177
PF-06700841 178
PF-06741086 179
PF-06751979 180
PF-06753512 181
PF-06755990 182
PF-06755992 183
PF-06801591 184
PF-06815345 185
Biologics for Undisclosed Indication 186
Biologics to Target PCSK-9 for Hypercholesterolemia 187
CE-355621 188
Drugs for Duchenne Muscular Dystrophy 189
GIBH-1008 190
GIBH-1010 191
GIBH-1018 192
GL-2045 193
HSD-621 194
J-17 195
Monoclonal Antibodies for Solid Tumor 196
MOR-8457 197
NIC7-DT 198
PD-0360324 199
PF-01247324 200
PF-06380101 201
PF-06447475 202
PF-06671008 203
PF-1355 204
PF-3845 205
PF-4989216 206
PF-5006739 207
PNU-120596 208
Proteins to Agonize MC4R for Obesity 209
RBT-301 210
….. Continue

Inquire for more information @ https://www.wiseguyreports.com/enquiry/pfizer-inc-product-pipeline-review-2016 .

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
16468459349
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.